Current Research in Translational Medicine

Scope & Guideline

Catalyzing Change in the Landscape of Translational Medicine

Introduction

Welcome to your portal for understanding Current Research in Translational Medicine, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2452-3186
PublisherELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 2016 to 2024
AbbreviationCURR RES TRANSL MED / Curr. Res. Transl. Med.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE

Aims and Scopes

Current Research in Translational Medicine focuses on bridging the gap between laboratory research and clinical applications, with a strong emphasis on hematological malignancies and innovative therapies. The journal aims to publish high-quality research that contributes to the understanding and management of various medical conditions, particularly through translational approaches.
  1. Hematological Malignancies:
    The journal consistently publishes research related to hematological cancers, including acute myeloid leukemia, lymphoma, and multiple myeloma, focusing on novel treatments and therapeutic strategies.
  2. Translational Research:
    A core aim is to translate laboratory findings into clinical applications, emphasizing studies that bridge experimental and clinical medicine.
  3. Cell and Gene Therapy:
    Research on cell-based therapies, particularly CAR-T cell therapy and stem cell transplantation, is a significant focus, highlighting advancements in treatment methodologies.
  4. Immunotherapy:
    The journal covers emerging immunotherapeutic strategies, investigating their efficacy and safety in treating various malignancies.
  5. Biomarkers and Diagnostics:
    There is a strong emphasis on identifying biomarkers for disease prognosis and treatment response, contributing to personalized medicine.
  6. Regenerative Medicine:
    Research involving stem cells and regenerative therapies is prevalent, showcasing innovative approaches to repair and regenerate damaged tissues.
  7. Clinical Guidelines and Best Practices:
    The journal also addresses clinical practices through guidelines and recommendations for managing hematological disorders.
Current Research in Translational Medicine is witnessing a surge in certain emerging themes that reflect the evolving landscape of medical research. This section outlines these trending areas, which are gaining prominence in recent publications.
  1. CAR-T Cell and Novel Immunotherapies:
    The increasing focus on CAR-T cell therapy and other immunotherapeutic approaches highlights the journal's commitment to cutting-edge treatments and their applications in hematological malignancies.
  2. Next-Generation Sequencing and Genomics:
    There is a growing trend towards incorporating genomic technologies such as next-generation sequencing, which aids in understanding the genetic underpinnings of diseases and personalizing treatment.
  3. Biomarker Discovery and Application:
    Research aimed at discovering and validating biomarkers for various hematological conditions is on the rise, enhancing the capabilities of precision medicine.
  4. Artificial Intelligence and Data Analytics:
    The integration of AI and data analytics in predicting treatment outcomes and patient responses is emerging as a significant trend, reflecting the journal's adaptation to technological advancements.
  5. Regenerative and Stem Cell Therapies:
    An increasing number of studies are exploring the potential of regenerative medicine and stem cell therapies, indicating a shift towards innovative approaches in treatment.
  6. Clinical Guidelines and Evidence-Based Practices:
    There is a noticeable trend towards publishing clinical guidelines and recommendations, aiming to standardize practices and improve patient care in hematological oncology.

Declining or Waning

While Current Research in Translational Medicine maintains a robust focus on hematological disorders and innovative therapies, certain themes have shown signs of decline in recent publications. This section highlights these waning areas.
  1. Solid Tumor Research:
    Research specifically focused on solid tumors has decreased, indicating a shift towards hematological malignancies and therapies related to blood cancers.
  2. Traditional Pharmacotherapy:
    There appears to be a reduction in studies centered on conventional pharmacological treatments, as innovative therapies like immunotherapy and gene therapy become more prominent.
  3. Infectious Disease Research:
    While COVID-19 research was significant during the pandemic, the volume of papers addressing infectious diseases outside the context of hematological malignancies has lessened.
  4. Basic Science Studies:
    There is a noticeable decline in purely basic science research that does not directly translate to clinical applications, as the journal increasingly emphasizes translational studies.

Similar Journals

Revista Romana de Medicina de Laborator

Pioneering Research for a Healthier Tomorrow
Publisher: SCIENDOISSN: 1841-6624Frequency: 4 issues/year

Revista Romana de Medicina de Laborator is a prominent open-access journal published by SCIENDO, dedicated to the field of medical laboratory technology and biochemistry. Since its inception, this journal has been a vital platform for disseminating research findings and advancements in laboratory medicine. With an ISSN of 1841-6624 and E-ISSN 2284-5623, it has served the academic community since 2008 and has embraced an open-access model since 2013, ensuring that valuable research is accessible to all. While it features niche rankings in Scopus for areas such as Medical Laboratory Technology and Clinical Biochemistry, it consistently strives to engage researchers, professionals, and students. Its rich collection of articles highlights innovative techniques and methodologies, supporting the ongoing development of laboratory practices. Although its coverage in Scopus has been discontinued, the journal continues to publish high-quality studies that contribute significantly to the field, fostering knowledge exchange essential for advancing medical science.

CURRENT MOLECULAR MEDICINE

Connecting Science to Medicine for a Healthier Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1566-5240Frequency: 10 issues/year

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

Stem Cells Translational Medicine

Unlocking the Potential of Stem Cell Technology
Publisher: OXFORD UNIV PRESSISSN: 2157-6564Frequency: 12 issues/year

Stem Cells Translational Medicine, published by Oxford University Press, is a leading open-access journal that has been at the forefront of stem cell research since its launch in 2012. With an impressive impact across various categories, it occupies Q2 in Cell Biology and is highly recognized in Q1 for both Developmental Biology and Miscellaneous Medicine in 2023. Its strong Scopus rankings highlight its significance in the fields of Biochemistry, Genetics, and Molecular Biology, achieving an outstanding percentile ranking of 93rd in Developmental Biology. The journal provides a pivotal platform for researchers, professionals, and students to publish and access cutting-edge findings that contribute to the understanding and application of stem cell technology. With a commitment to disseminating high-quality scientific knowledge, Stem Cells Translational Medicine plays a vital role in advancing research and innovation within the rapidly evolving landscape of regenerative medicine.

Experimental Hematology & Oncology

Unveiling Innovations in Cancer and Hematological Science
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Unraveling the Complexities of Immunology and Oncology
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Cell Reports Medicine

Transforming discoveries into medical advancements for all.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

JOURNAL OF MOLECULAR MEDICINE-JMM

Exploring the Intersection of Biochemistry and Clinical Innovation.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Blood Science

Connecting Researchers to Breakthroughs in Hematology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

Indian Journal of Hematology and Blood Transfusion

Exploring Innovations in Blood Disorders and Transfusion Science
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

npj Regenerative Medicine

Shaping the Future of Therapeutic Advancements.
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Regenerative Medicine, published by NATURE PORTFOLIO, is at the forefront of research and innovation in the field of regenerative medicine, fostering a deep understanding of cellular and molecular processes that can be leveraged for therapeutic advancements. Launched as an Open Access journal since 2016, it ensures wide dissemination of knowledge, allowing researchers, professionals, and students to access high-quality articles without barriers. With an impressive impact, it holds Q1 ratings across multiple categories including Biomedical Engineering, Cell Biology, Developmental Biology, and Medicine (miscellaneous) as of 2023, indicating its critical role in shaping contemporary scientific discourse. The journal ranks notably within the top 10% in multiple Scopus categories, indicating its commitment to publishing pioneering research that addresses pressing challenges in regenerative therapies. Addressing the dynamic convergence of disciplines, npj Regenerative Medicine is poised to not only impact academic thought but also translate into clinical applications, making it a pivotal resource for those invested in the future of medicine.